EmbectaMEX:EMBC 53 Pretax Margin % is 4.28% as of Mar. 2026, which is 81% below its 10-year median of 22.72. GuruFocus rates MEX:EMBC with a GF Score™ of 53/100 and a GF Value™ of MXN1,817.27. The stock has 6 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Embecta ranks better than 80.54% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Embecta's Pre-Tax Income for the
three
months ended in Mar. 2026 was MXN171 Mil. Embecta's Revenue for the
three
months ended in Mar. 2026 was MXN4,000 Mil. Therefore, Embecta's pretax margin for the quarter that ended in Mar. 2026 was 4.28%.
The historical rank and industry rank for Embecta's Pretax Margin % or its related term are showing as below:
MEX:EMBC'
s Pretax Margin % Range Over the Past 10 Years
Min: 3.94 Med: 22.72 Max: 45.09
Current: 16.27
MEX:EMBC's Pretax Margin % is ranked better than 80.54% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.61
vs MEX:EMBC: 16.27
Embecta (MEX:EMBC) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Embecta Pretax Margin % Related Terms
Embecta Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Embecta's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:EMBC vs PDEX, STXS, SMTI: Pretax Margin % Comparison
For the Medical Instruments & Supplies subindustry, Embecta's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Embecta Pretax Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Embecta's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Embecta's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Embecta (MEX:EMBC) has a Pretax Margin % of 4.28% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Embecta and its competitors. This is 81% below median its historical median of 22.72. Over the past decade, Embecta's Pretax Margin % has ranged from 3.94 to 45.09. According to the industry distribution chart, Embecta ranks #159 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 19.5%.
Is Embecta's Pretax Margin % too high?
Embecta's current Pretax Margin % of 4.28% is 81% below median its 10-year median of 22.72. Over the past 10 years, this metric has ranged from a low of 3.94 to a high of 45.09. The Medical Devices & Instruments industry median Pretax Margin % is 2.61. Embecta's value of 4.28% is 64% above this industry median. Based on the distribution chart, Embecta ranks #159 out of 817 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Embecta has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Embecta's Pretax Margin % compare to PDEX and STXS?
According to the Medical Devices & Instruments industry distribution chart, Embecta ranks #159 out of 817 companies for Pretax Margin %. This places Embecta in the top 20% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 2.61. Embecta's value of 4.28% is 64% above this benchmark. Historically, Embecta's own Pretax Margin % has ranged from 3.94 to 45.09 over the past decade. While the company's 10-year median is 22.72 vs. the industry median of 2.61, Embecta has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Devices & Instruments company?
The median Pretax Margin % among Medical Devices & Instruments companies is 2.61, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Embecta's current Pretax Margin % of 4.28% is 64% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Embecta and its competitors. For the Medical Devices & Instruments industry, the median Pretax Margin % is 2.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Embecta's current Pretax Margin % is 4.28%, which is 81% below median its own 10-year median of 22.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embecta stock overvalued right now?
Embecta (MEX:EMBC) has a current Pretax Margin % of 4.28%. The stock's GF Value™ is MXN1,817.27, compared to a current price of MXN497.96 — trading 72.6% below its estimated fair value. The current Pretax Margin % is 4.28%, which is 81% below median its 10-year median of 22.72 and 64% above the Medical Devices & Instruments industry median of 2.61. Embecta's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Embecta (MEX:EMBC), the current Pretax Margin % is 4.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Embecta (MEX:EMBC) Overvalued in 2026?
Based on GuruFocus' analysis, Embecta stock appears to be undervalued.
The current stock price of MXN497.96 is trading 72.6% below its estimated GF Value™ of MXN1,817.27.
Key valuation signals for MEX:EMBC:
Pretax Margin %: 4.28% (81% below median its 10-year median of 22.72)
GF Value™: MXN1,817.27 vs. price of MXN497.96 (72.6% below fair value)
Industry Position: 64% above the Medical Devices & Instruments median (#159 of 817)
No single metric tells the full story. See the MEX:EMBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
53GF Score
Get the complete analysis for MEX:EMBC
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:EMBC has been successfully added to your 
